Pliant Therapeutics Inc (PLRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.16+2.65%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PLRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue Phase 1b trial enrollment and data generation for PLN-101095 in ICI-refractory solid tumors.
Newly stated in 2026-Q1. Management initiated the FORTIFY Phase 1b trial and dosed the first patient in April 2026, with interim data expected in 2027. No financial metrics directly quantify progress yet, but the clinical trial initiation matches management's stated development focus.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Initiated FORTIFY Phase 1b trial ahead of schedule and dosed first patient in April.”
Develop and advance integrin receptor-based drug delivery programs for selective tissue targeting.
Newly stated in 2026-Q1. Management described ongoing preclinical proof-of-concept studies for integrin-targeted drug delivery. No revenue or financial metrics are available to measure progress, indicating early-stage development with limited financial delivery so far.
“Preclinical proof-of-concept studies ongoing for integrin-targeted siRNA delivery.”
Preserve cash, cash equivalents, and short-term investments to support operations through mid-2028.
Stated in 2 of last 2 quarters. Cash and equivalents declined from $192.4 million at 2025-Q4 to $172.4 million at 2026-Q1, consistent with ongoing operations. Management expects this capital to fund operations into the second half of 2028, indicating delivery on maintaining sufficient capital with a moderate cash burn.
“Cash, cash equivalents and short-term investments of $172.4 million expected to fund operations into second half of 2028.”
“Cash, cash equivalents and short-term investments of $192.4 million expected to fund operations into second half of 2028.”
Lower R&D and G&A expenses through workforce reductions and program terminations.
Newly stated in 2026-Q1. Management reported significant reductions in R&D expenses from $43.4 million to $13.6 million and G&A expenses from $15.5 million to $8.2 million compared to the prior year quarter, driven by workforce reductions and program terminations. This reflects delivering on cost reduction priorities with substantial expense declines.
“R&D expenses $13.6M vs $43.4M prior year; G&A expenses $8.2M vs $15.5M prior year due to headcount reduction.”
Appoint new directors and manage retirements to strengthen governance.
Newly stated in 2026-Q2. Management reported appointment of two new directors and retirement of three directors at the Annual Meeting, reflecting active board transitions. This priority is recent with no financial metrics but indicates governance focus.
“Board appointed two new directors and three directors retired effective at Annual Meeting.”
Over the trailing year it converted -0.78x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, the broad stock market, long-term interest rates (low R² over the window).
10 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.